
Sign up to save your podcasts
Or


This piece is highlighted because of its significance. Please check out the rest of TopMedTalk's coverage of the conference on our website - www.topmedtalk.com
Regular listeners will appreciate the importance of the PeriOperative ISchemic Evaluation-3 Trial (POISE-3). Here we highlight a conversation containing late breaking news on the subject.
The New England Journal of Medicine is here: https://www.nejm.org/doi/full/10.1056/NEJMoa2201171
Presented by Desiree Chappell and Monty Mythen with their guests Frederic Michard, MD of MiCo Consulting and Daniel Sessler, Michael Cudahy Professor and Chair at Cleveland Clinic, Director of The Outcomes Research Consortium.
By TopMedTalk4.8
3535 ratings
This piece is highlighted because of its significance. Please check out the rest of TopMedTalk's coverage of the conference on our website - www.topmedtalk.com
Regular listeners will appreciate the importance of the PeriOperative ISchemic Evaluation-3 Trial (POISE-3). Here we highlight a conversation containing late breaking news on the subject.
The New England Journal of Medicine is here: https://www.nejm.org/doi/full/10.1056/NEJMoa2201171
Presented by Desiree Chappell and Monty Mythen with their guests Frederic Michard, MD of MiCo Consulting and Daniel Sessler, Michael Cudahy Professor and Chair at Cleveland Clinic, Director of The Outcomes Research Consortium.

1,866 Listeners

498 Listeners

296 Listeners

886 Listeners

1,471 Listeners

87,134 Listeners

3,335 Listeners

111,970 Listeners

56,511 Listeners

1,150 Listeners

185 Listeners

428 Listeners

243 Listeners

15,833 Listeners

271 Listeners